MedTrace Logo

Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

NCT01720719 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-02-03

No results posted yet for this study

Summary

The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.

Conditions

Interventions

DRUG

atorvastatin

Oral atorvastatin 20mg, qd, for 24 weeks

DRUG

Vitamin E

Oral Vitamin E 300mg, qd, for 24 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Xin Gao

    lead OTHER

Principal Investigators

  • Xin Gao, doctor · Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720719 on ClinicalTrials.gov